The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

According to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the p...

Alkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...

The group now has nearly 120 approvals from the USFDA and so far filed 300 abbreviated new drug applications (ANDAs), Cadila Healthcare sai...

Diabetes estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide.

Drug firm Zydus Cadila has received final nod from the US health regulator to sell anti-diabetics Glyburide and Metformin Hcl tablets in th...

India's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...

Tenglyn, is a product belonging to a new class of drugs called gliptins, a segment that has witnessed the most aggressive growth among all ...

Earlier, in an interim order, a division bench of the high Court had restrained Glenmark from making or selling its drug, used for treatmen...

With Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.

In a grim reminder of the rise of lifestyle diseases, anti-diabetic molecule has for the first time become the largest-selling formulation ...

The Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.

The court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...

The development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-...

Healthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs Cont...